China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced that its market filing for a long-acting insulin analogue, a Category 1 biologic product, has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant milestone for Hengrui as it seeks to bring China’s first homegrown long-acting insulin analogue to market, targeting the treatment of adult type 2 diabetes.
Product Highlights and Market Position
Hengrui’s long-acting insulin analogue is described as having several key advantages, including stable onset, extended duration of drug efficacy, and a low risk of nocturnal hypoglycemia. These features position the product as a competitive alternative to existing treatments in the global market. Similar products currently available include Novo Nordisk’s Tresiba (insulin degludec) and Sanofi’s Toujeo (insulin glargine), both of which have established market presence.
Implications for Diabetes Treatment in China
The acceptance of Hengrui’s market filing by the NMPA highlights the growing capabilities of China’s domestic pharmaceutical industry in developing innovative biologic products. With type 2 diabetes representing a significant health challenge in China, Hengrui’s long-acting insulin analogue could offer a new treatment option for millions of patients. The company’s efforts underscore its commitment to advancing diabetes care and improving patient outcomes through innovative therapies.-Fineline Info & Tech
Leave a Reply